Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 42 full-time employees. The firm develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The firm`s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The firm commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
Website: biocept.com



Growth: Bad revenue growth rate -64.7%, there is slowdown compared to average historical growth rates 79.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -33.3%. On average the margin is decreasing steadily. Gross margin is low, -3.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$6.9 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 98.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.8x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: BIOC
Share price, USD:  (0.0%)0.4349
year average price 0.4349  


year start price 0.4349 2025-01-08

max close price 0.4349 2025-01-08

min close price 0.4349 2025-01-08

current price 0.4349 2026-01-07
Common stocks: 17 620 668

Dividend Yield:  0.0%
EV / Sales: 0.0x
Margin (EBITDA LTM / Revenue): -33.3%
Fundamental value created in LTM:
Market Cap ($m): 8
Net Debt ($m): -6
EV (Enterprise Value): 2
Price to Book: 26.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-08-30Seeking Alpha

Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)

2023-08-25InvestorPlace

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

2023-08-14Proactive Investors

Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference

2023-06-21Proactive Investors

Biocept appoints Antonino Morales as president and chief executive officer

2023-06-05Proactive Investors

Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases

2023-05-25InvestorPlace

Why Is Biocept (BIOC) Stock Down 42% Today?

2023-05-17Proactive Investors

Biocept shares to commence trading on split-adjusted basis

2023-04-17Proactive Investors

Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BIOC BIOC BIOC BIOC BIOC
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-08-14 2023-05-10 2023-04-17 2022-11-21 2022-11-10
acceptedDate 2023-08-14 16:31:27 2023-05-10 17:05:11 2023-04-17 17:18:48 2022-11-21 16:10:55 2022-11-10 16:22:47
calendarYear 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2
revenue 589 000 673 000 -10M 6M 11M
costOfRevenue 3M 3M 4M 6M 8M
grossProfit -2M -2M -15M -189 000 3M
grossProfitRatio -3.329 -3.499 1.419 -0.034 0.244
researchAndDevelopmentExpenses 409 000 1M 1M 1M 2M
generalAndAdministrativeExpenses 3M 3M 2M 3M 4M
sellingAndMarketingExpenses 250 000 715 000 835 000 975 000 2M
sellingGeneralAndAdministrativeExpenses 4M 4M 3M 4M 6M
otherExpenses 0 0 3000 0 0
operatingExpenses 4M 5M 4M 5M 8M
costAndExpenses 7M 8M 8M 11M 16M
interestIncome 0 0 0 0 0
interestExpense 50 000 46 000 47 000 52 000 155 000
depreciationAndAmortization 370 000 614 000 441 000 491 000 810 000
ebitda -3M -6M -18M -5M -4M
ebitdaratio -5.452 -9.634 1.766 -0.91 -0.404
operatingIncome -6M -7M -19M -6M -5M
operatingIncomeRatio -10.38 -10.547 1.809 -0.998 -0.48
totalOtherIncomeExpensesNet 2M -46 000 -44 000 32 000 -155 000
incomeBeforeTax -4M -7M -19M -6M -5M
incomeBeforeTaxRatio -6.165 -10.615 1.813 -0.992 -0.495
incomeTaxExpense 0 92 000 -125 000 -32 000 0
netIncome -4M -7M -19M -6M -5M
netIncomeRatio -6.165 -10.752 1.801 -0.987 -0.495
eps -3503.04 -12.46 -1.09 -0.32 -0.34
epsdiluted -3503.04 -12.32 -1.09 -0.32 -0.34
weightedAverageShsOut 1036.529 580 813 17M 17M 15M
weightedAverageShsOutDil 1036.529 587 355 17M 17M 16M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BIOC BIOC BIOC BIOC BIOC
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-08-14 2023-05-10 2023-04-17 2022-11-21 2022-11-10
acceptedDate 2023-08-14 16:31:27 2023-05-10 17:05:11 2023-04-17 17:18:48 2022-11-21 16:10:55 2022-11-10 16:22:47
calendarYear 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 7M 7M 13M 18M 23M
shortTermInvestments 0 0 0 0 0
cashAndShortTermInvestments 7M 7M 13M 18M 23M
netReceivables 800 000 1M 2M 16M 17M
inventory 551 000 704 000 757 000 2M 2M
otherCurrentAssets 876 000 500 000 538 000 949 000 1M
totalCurrentAssets 9M 9M 16M 37M 44M
propertyPlantEquipmentNet 13M 14M 14M 14M 14M
goodwill 0 0 0 0 0
intangibleAssets 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0
longTermInvestments 0 0 0 0 0
taxAssets 0 0 0 0 0
otherNonCurrentAssets 386 000 386 000 386 000 392 000 496 000
totalNonCurrentAssets 13M 14M 15M 14M 14M
otherAssets 0 0 0 0 0
totalAssets 22M 23M 31M 51M 58M
accountPayables 1M 2M 2M 3M 5M
shortTermDebt 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0
deferredRevenue 0 0 0 0 0
otherCurrentLiabilities 2M 1M 2M 2M 3M
totalCurrentLiabilities 5M 4M 6M 7M 10M
longTermDebt 10M 10M 10M 10M 10M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 7M 6M 6M 11M 6M
totalNonCurrentLiabilities 17M 16M 17M 16M 16M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 0 0 12M 12M 12M
totalLiabilities 22M 21M 22M 24M 26M
preferredStock 0 0 0 0 0
commonStock 0 2000 2000 2000 2000
retainedEarnings -309M -306M -298M -280M -274M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0
othertotalStockholdersEquity 309M 308M 307M 307M 307M
totalStockholdersEquity 290 000 2M 9M 28M 32M
totalEquity 290 000 2M 9M 28M 32M
totalLiabilitiesAndStockholdersEquity 22M 23M 31M 51M 58M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 22M 23M 31M 51M 58M
totalInvestments 0 0 0 0 0
totalDebt 12M 12M 12M 12M 12M
netDebt 5M 5M -788 000 -6M -11M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol BIOC BIOC BIOC BIOC BIOC
reportedCurrency USD USD USD USD USD
cik 1M 1M 1M 1M 1M
fillingDate 2023-08-14 2023-05-10 2023-04-17 2022-11-21 2022-11-10
acceptedDate 2023-08-14 16:31:27 2023-05-10 17:05:11 2023-04-17 17:18:48 2022-11-21 16:10:55 2022-11-10 16:22:47
calendarYear 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2
netIncome -4M -7M -19M -6M -8M
depreciationAndAmortization 370 000 614 000 438 000 407 000 810 000
deferredIncomeTax 0 -336 000 0 0 0
stockBasedCompensation 209 000 316 000 -137 000 462 000 3M
changeInWorkingCapital 2M 20 000 14M 378 000 -663 000
accountsReceivables 312 000 1M 14M 2M -4M
inventory 153 000 53 000 1M 352 000 402 000
accountsPayables 347 000 -39 000 -1M -2M -3M
otherWorkingCapital 882 000 -1M 387 000 120 000 0
otherNonCashItems -2M 336 000 141 000 222 000 0
netCashProvidedByOperatingActivities -3M -6M -4M -4M -5M
investmentsInPropertyPlantAndEquipment -97 000 -91 000 -136 000 -356 000 -315 000
acquisitionsNet 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0
otherInvestingActivites 75 000 0 0 0 0
netCashUsedForInvestingActivites -22 000 -91 000 -136 000 -356 000 -315 000
debtRepayment 0 0 -59 000 -621 000 -501 000
commonStockIssued 4M 396 000 1000 145 000 94 000
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 3M 162 000 -688 000 0 -242 000
netCashUsedProvidedByFinancingActivities 3M 162 000 -746 000 -476 000 -649 000
effectOfForexChangesOnCash 0 0 0 0 0
netChangeInCash -141 000 -6M -5M -5M -5M
cashAtEndOfPeriod 7M 7M 13M 18M 23M
cashAtBeginningOfPeriod 7M 13M 18M 23M 28M
operatingCashFlow -3M -6M -4M -4M -5M
capitalExpenditure -97 000 -91 000 -136 000 -356 000 -315 000
freeCashFlow -3M -6M -4M -4M -5M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2022 q3
2022-11-28 ET (fiscal 2022 q3)

SEC forms

Show financial reports only

SEC form 8
2023-08-22 00:00 ET
Biocept reported for 2023 q2
SEC form 10
2023-08-14 16:31 ET
Biocept reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Biocept reported for 2023 q2
SEC form 6
2023-06-21 16:06 ET
Biocept published news for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Biocept reported for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Biocept reported for 2023 q1
SEC form 8
2023-04-17 00:00 ET
Biocept published news for 2023 q1
SEC form 10
2023-04-17 00:00 ET
Biocept reported for 2022 q4
SEC form 6
2023-04-03 08:00 ET
Biocept published news for 2023 q1
SEC form 6
2023-03-20 08:00 ET
Biocept published news for 2022 q4
SEC form 6
2023-01-06 07:01 ET
Biocept published news for 2022 q4
SEC form 8
2023-01-06 00:00 ET
Biocept published news for 2022 q4
SEC form 6
2022-11-21 16:31 ET
Biocept published news for 2022 q3
SEC form 10
2022-11-21 16:10 ET
Biocept reported for 2022 q3
SEC form 8
2022-11-21 00:00 ET
Biocept reported for 2022 q3
SEC form 10
2022-11-21 00:00 ET
Biocept reported for 2022 q3
SEC form 6
2022-11-18 08:10 ET
Biocept published news for 2022 q3
SEC form 6
2022-11-14 16:56 ET
Biocept published news for 2022 q3
SEC form 6
2022-11-14 08:01 ET
Biocept published news for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Biocept published news for 2022 q3
SEC form 10
2022-11-10 16:22 ET
Biocept reported for 2022 q2
SEC form 10
2022-11-10 00:00 ET
Biocept reported for 2022 q2
SEC form 6
2022-10-19 16:06 ET
Biocept published news for 2022 q3
SEC form 6
2022-08-22 16:34 ET
Biocept published news for 2022 q2
SEC form 6
2022-08-16 08:06 ET
Biocept published news for 2022 q2
SEC form 6
2022-07-14 06:07 ET
Biocept published news for 2022 q2
SEC form 6
2022-07-13 16:04 ET
Biocept published news for 2022 q2
SEC form 6
2022-06-27 16:06 ET
Biocept published news for 2022 q1
SEC form 6
2022-06-13 16:06 ET
Biocept published news for 2022 q1
SEC form 6
2022-05-24 16:01 ET
Biocept published news for 2022 q1
SEC form 8
2022-05-24 00:00 ET
Biocept reported for 2022 q1
SEC form 10
2022-05-23 14:42 ET
Biocept reported for 2022 q1
SEC form 10
2022-05-23 00:00 ET
Biocept reported for 2022 q1
SEC form 6
2022-05-16 16:12 ET
Biocept published news for 2022 q1
SEC form 6
2022-05-02 16:11 ET
Biocept published news for 2022 q1
SEC form 6
2022-04-12 16:02 ET
Biocept published news for 2022 q1
SEC form 6
2022-04-07 06:05 ET
Biocept published news for 2022 q1
SEC form 8
2022-04-07 00:00 ET
Biocept published news for 2022 q1
SEC form 10
2022-04-05 17:26 ET
Biocept published news for 2021 q4
SEC form 10
2022-04-05 00:00 ET
Biocept published news for 2021 q4
SEC form 6
2022-04-01 16:04 ET
Biocept published news for 2022 q1
SEC form 6
2022-04-01 06:04 ET
Biocept published news for 2022 q1
SEC form 8
2022-04-01 00:00 ET
Biocept published news for 2022 q1
SEC form 6
2022-03-24 16:02 ET
Biocept published news for 2021 q4
SEC form 6
2022-03-08 16:02 ET
Biocept published news for 2021 q4
SEC form 6
2022-02-16 16:21 ET
Biocept published news for 2021 q4
SEC form 6
2022-02-14 21:17 ET
Biocept published news for 2021 q4
SEC form 6
2022-01-31 07:03 ET
Biocept published news for 2021 q4
SEC form 6
2021-11-22 16:34 ET
Biocept published news for 2021 q3
SEC form 10
2021-11-15 16:43 ET
Biocept published news for 2021 q3
SEC form 6
2021-11-15 16:12 ET
Biocept published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Biocept published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Biocept published news for 2021 q3
SEC form 10
2021-08-16 16:37 ET
Biocept published news for 2021 q2
SEC form 6
2021-08-16 16:12 ET
Biocept published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Biocept published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Biocept published news for 2021 q2
SEC form 6
2021-07-21 08:37 ET
Biocept published news for 2021 q2
SEC form 6
2021-07-20 16:28 ET
Biocept published news for 2021 q2
SEC form 6
2021-07-12 16:46 ET
Biocept published news for 2021 q2
SEC form 6
2021-06-15 16:30 ET
Biocept published news for 2021 q1
SEC form 6
2021-05-13 06:30 ET
Biocept published news for 2021 q1
SEC form 10
2021-05-12 17:00 ET
Biocept published news for 2021 q1
SEC form 6
2021-05-12 16:14 ET
Biocept published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Biocept published news for 2021 q1
SEC form 6
2021-04-30 16:18 ET
Biocept published news for 2021 q1
SEC form 10
2021-03-31 16:22 ET
Biocept published news for 2020 q4
SEC form 6
2021-03-29 16:12 ET
Biocept published news for 2020 q4
SEC form 10
2020-11-13 21:39 ET
Biocept published news for 2020 q3
SEC form 6
2020-11-12 16:22 ET
Biocept published news for 2020 q3
SEC form 6
2020-10-21 08:32 ET
Biocept published news for 2020 q3